Piper Jaffray analyst Charles Duncan reiterates Overweight rating and $15 price target on Cytokinetics Inc. (NASDAQ: CYTK), suggesting the company’s ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Cantor Fitzgerald Remains Bullish on Cytokinetics (CYTK) February 17, 2017 7:50 AM FBR Capital Reiterates Outperform on Cytokinetics (CYTK) Following 4Q February 17, 2017 7:17 AM Cytokinetics (CYTK) Tops Q4 EPS by 43cFebruary 16, 2017 4:06 PM Cytokinetics, Inc. Reports Fourth Quarter 2016 Financial ResultsFebruary 16, 2017 4:00 PM